building muscle on semaglutide and Body Mass bimagrumab semaglutide Lilly stops trial

Smarter health-focused brands are instead introducing high-protein, high-fiber, and nutrient-dense options using terms like balanced and nutrient-rich, while avoiding direct references to GLP-1

Earlier this month, (June 2025), Novo inked a deal worth up to $815 million with Deep Apple Therapeutics, a South San Francisco-based company specializing in small-molecule drug discovery to discover, develop, and commercialize oral small-molecule therapeutics directed at a non-incretin G protein-coupled receptors (GPCR) target for cardiometabolic diseases, including obesity, in a deal worth up to $812 million

Patients who stop treatment often regain weight, especially if lifestyle changes havent been fully integrated

Retatrutide is currently available through research peptide suppliers while clinical trials continue

Furthermore, both of them have serious side effects, with each carrying a boxed warning regarding the potential risk of thyroid cancer